OPEN The New England journal of medicine | 4 Oct 2018
SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, A Chiappori, KH Lee, M de Wit, BC Cho, M Bourhaba, X Quantin, T Tokito, T Mekhail, D Planchard, YC Kim, CS Karapetis, S Hiret, G Ostoros, K Kubota, JE Gray, L Paz-Ares, J de Castro Carpeño, C Faivre-Finn, M Reck, J Vansteenkiste, DR Spigel, C Wadsworth, G Melillo, M Taboada, PA Dennis and M Özgüroğlu
An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression-free survival, as compared with placebo, among patients with stage III, unresectable non-small-cell lung cancer (NSCLC) who did not have disease progression after concurrent chemoradiotherapy. Here we report the results for the second primary end point of overall survival.
* Data courtesy of Altmetric.com